Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BDR-165
- Development stage
- Preclinical
- Lead developer
- MDimune
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
01
Overview
BDR-165 is a **preclinical cancer therapeutic program** from **BioDrone Therapeutics** built on the company's **cell-derived vesicle** platform for **small-molecule delivery**. The asset appears to use **cell-derived extracellular vesicles as a nanocarrier** to deliver an incorporated small-molecule payload to tumors, with the intended goal of improving tumor targeting, payload stability, and potentially the safety or therapeutic index of the small-molecule cargo. Publicly available pipeline information identifies the program only at a high level as a **CDV small-molecule delivery candidate for cancer**; no specific payload, molecular target, route of administration, formulation details, or tumor subtype have been disclosed.
- Other names
- BioDrone Therapeutics CDV small molecule delivery programBDR-165 cell-derived vesicle small molecule delivery nanocarrierBDR165 cell-derived vesicle small molecule delivery nanocarrierBDR 165 cell-derived vesicle small molecule delivery nanocarrier
Beyond the preview
Go deeper on BDR-165.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BDR-165.